GMED vs SYK
Globus Medical vs Stryker Corporation — AI-powered side-by-side comparison
GMED
Globus Medical
68
Buy
VS
SYK
Stryker Corporation
70
Buy
| Metric | GMED | SYK |
|---|
| AI Score |
68
|
70
|
| Price |
$85.87
|
$338.83
|
| P/E Ratio |
21.64×
|
34.86×
|
| ROE |
11.8%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
65.2%
|
| Debt / Equity |
0.02×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
70.3
|
49.4
|
| Beta |
0.954
|
0.771
|
| Expected Upside |
+0.5%
|
+10.4%
|
AI Committee View
Current Innellis committee reasoning for GMED versus SYK.
SYK leads by 2 points.
SYK scores 70/100 (Buy) versus GMED at 68/100 (Buy).
GMED Committee View
60% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 70 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 70 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Bollinger bandwidth of 18.3% signals elevated volatility — Risk
SYK Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.33 across 31 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical